An international group of experts in haematology have called for an urgent review of the way adverse events in haematological cancers are reported and managed. In an era when targeted therapies have transformed previously incurable blood cancers to allow patients to live with disease for many years, the traditional focus on acute high grade adverse ...
New approach needed on adverse events in haematological cancers
By Michael Woodhead
26 Jun 2018